ClinicalTrials.gg
RecruitingNCT07237386Updated Nov 19, 2025

Comparing the Ceriter Stride One, a Pressure-sensitive Smart Insole, With Gait Parameters Measured on the GRAIL in Neurological Populations

An interventional study of Wearing smart insoles in Stroke, Incomplete Spinal Cord Injury and Traumatic Brain Injury, sponsored by University Hospital, Ghent. Recruiting at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Stroke by University Hospital, Ghent — 9 open to participants now, 9 under way, none of them phase 3. Stroke · University Hospital, Ghent.

Planned enrollment
7th of 13
30 · median 30
Started
2025
with 2 others
No phase
13 of 18
6 open now
Registered
16th of 18
by date

Among the 18 studies in Stroke by University Hospital, Ghent, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, and was the 16th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

9 of the 18 studies in Stroke by University Hospital, Ghent are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Stroke by University Hospital, Ghent, or all of them as a file.
02

Study summary

Ceriter Stride-One soles have been available on the market for several years. One of the features of these soles is that they can measure gait parameters while patients walk around in a functional environment. This can provide a more realistic picture of gait patterns compared to measurements taken in a laboratory setting.

At UZ Ghent, we use an advanced gait lab to measure gait parameters before and after a training period on this system, the GRAIL system. We measure similar parameters to the Ceriter Stride-One soles (support phase, swing phase, pressure on the left leg and on the right leg). In this study, we would apply these insoles to patients who are tested on the GRAIL system, according to standard care, during the test in order to compare the parameters measured by the insoles and the parameters measured by the GRAIL system. This information will give us more insight into the accuracy of the data measured with these soles so that we can apply them in future studies conducted not in the gait lab but in functional environments.

Patients who are eligible for GRAIL therapy and are therefore routinely tested are patients who are admitted or undergoing outpatient rehabilitation at the rehabilitation centre of UZ Ghent after a brain injury, stroke, spinal cord injury or amputation. Given the subject of the research and the difficulty of fitting a sole into the shoe of a prosthetic leg, only people with brain and spinal cord injuries are asked to participate in the study.

Participants must be able to step onto the GRAIL treadmill with the help of one therapist and must be able to walk for at least six minutes. Participants have to weigh less than 120 kg (treadmill safety system restriction).

As standard in our setting, participants train for 5 weeks, twice a week for 30 minutes on the GRAIL treadmill. Before and after their training period, they walk on the GRAIL for about 2 minutes and we measure a number of gait parameters: speed, step width, step length, duration of the support phase and swing phase, and how much they support on their left and right legs.

Some of these parameters can also be measured by the Ceriter Stride One sole. The aim is to investigate how comparable these data are. If these data are sufficiently comparable, the soles can be used to measure the ratio of the support and swing phases during walking in everyday tasks or in environments other than a laboratory setting.

03

Conditions studied

  • Stroke
  • Incomplete Spinal Cord Injury
  • Traumatic Brain Injury
  • Acquired Brain Injury

Keywords

  • Gait
  • stroke
  • spinal cord injury
  • brain injury
  • smart insoles
  • spatiotemporal
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persons suffering a lesion of the central nervous system (stroke, incomplete spinal cord injury, acquired brain injury) who are admitted to the rehabilitation center of the Ghent University hospital or who follow therapy at the rehabilitation center of the Ghent University hospital as outpatients.
  • Patients need to be able to walk independently during at least 6 minutes without the need of an extra person (Functional ambulation category 3 or higher).

Exclusion criteria

Exclusion Criteria:

  • Severe orthopedic trauma or acute trauma of the lower limbs influencing walking
  • body weight that exceeds 120 kg.
  • severe dizziness that makes exercising in standing position impossible
  • severe cardio-pulmonary disorders that require monitoring during exercising
  • patients who do not understand the task that needs to be performed in this study.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Insoles

    This is the group wearing smart insoles, it is the only group

    Device: Wearing smart insoles

Interventions

  • DeviceWearing smart insoles

    Participants will wear Ceriter Stride One insoles during walking on an instrumented treadmill. Parameters (like stance phase duration and swing phase duration) measured by the insoles will be compared to the same parameters measured by the instrumented treadmill with accompanying 3D motion capture system.

06

What researchers measure

Primary outcomes

  1. Swing phase as a percentage of the duration of one stride

    For each leg the duration of the swing phase will be determined as a percentage of the duration of one stride. Using the GRAIL system this will be calculated as de duration between toe-off and the following heel contact of the same leg. Using the ceriter stride one insole this will be calculated by determining the toe-off and following heel contact based on a cut-off value using the pressure sensors in the insole. For both devices it will be expressed as a percentage of the duration of one stride.

    Time frame: Single point of assessment at inclusion

  2. Stance phase as a percentage of the duration of one stride

    For each leg the duration of the stance phase will be determined as a percentage of the duration of one stride. Using the GRAIL system this will be calculated as de duration between heel contact and the following toe-off of the same leg. Using the ceriter stride one insole this will be calculated by determining the heel contact and following toe-off based on a cut-off value using the pressure sensors in the insole. For both devices it will be expressed as a percentage of the duration of one stride.

    Time frame: Single point of assessment at inclusion

Secondary outcomes

  1. Stance phase as a percentage of the duration of one stride after 5 weeks

    For each leg the duration of the stance phase will be determined as a percentage of the duration of one stride. Using the GRAIL system this will be calculated as de duration between heel contact and the following toe-off of the same leg. Using the ceriter stride one insole this will be calculated by determining the heel contact and following toe-off based on a cut-off value using the pressure sensors in the insole. For both devices it will be expressed as a percentage of the duration of one stride.

    Time frame: Single point of assessment at 5 weeks after inclusion

  2. Swing phase as a percentage of the duration of one stride after 5 weeks

    For each leg the duration of the swing phase will be determined as a percentage of the duration of one stride. Using the GRAIL system this will be calculated as de duration between toe-off and the following heel contact of the same leg. Using the ceriter stride one insole this will be calculated by determining the toe-off and following heel contact based on a cut-off value using the pressure sensors in the insole. For both devices it will be expressed as a percentage of the duration of one stride.

    Time frame: Single point of assessment at 5 weeks after inclusion

  3. Ratio of stance phase duration

    The ratio of the stance phase duration of the paretic leg will be calculated compared to the non-paretic leg. Or if both legs are involved, the ratio of the most impaired leg on the least impaired leg. This will determine the asymmetry in stance phase duration during walking.

    Time frame: Single point of assessment at inclusion

  4. Ratio of stance phase duration after 5 weeks

    The ratio of the stance phase duration of the paretic leg will be calculated compared to the non-paretic leg. Or if both legs are involved, the ratio of the most impaired leg on the least impaired leg. This will determine the asymmetry in stance phase duration during walking.

    Time frame: Single point of assessment at 5 weeks after inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 10 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 19, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Sep 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07237386
Collaborators
University Ghent
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Oct 15, 2025
Primary completion
Sep 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Nov 19, 2025

Study contacts

Anke Van Bladel, Professor
Contact
anke.vanbladel@uzgent.be
+32468181632

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion